Zelluna Immunotherapy and Glycostem Therapeutics have teamed up to develop TCR cell therapies for cancers, including hard-to-treat solid tumors. The partnership will combine Zelluna’s T-cell receptors (TCR) with The Netherlands-based Glycostem’s umbilical cord-derived natural killer cells. The TCR-NK cells will be made at the latter’s manufacturing facility in the Netherlands. A Zelluna spokesman told us TCR-NKs can target a broader range of tumors than cell therapies made using chimeric antigen receptors (CARs). “Adoptive cell therapies, both CAR and TCR, use…